Skip To Main Content
Yinduo Zeng on Muck Rack

Yinduo Zeng

As seen in: Nature, Wiley Online Library, Cell Reports Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yinduo

Contact Yinduo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial

|
By Wenjing Wu, Yaping Yang, Haizhu Chen, Yongkui Lu, Yinduo Zeng, Jianli Zhao, Caiwen Du, Ying Lin, PeiJian Peng, Mei Huang, Ying Zhang, Quchang Ouyang, Linxiaoxiao Ding, Ziliang Cheng, Zhiyong Wu, Jinhui Ye, Kun Wang, Ying Lu, Guorong Zou, Jincai Zhong, Hong Wang, Daren Lin, De Zeng, Qianjun Chen, Liqun Zou, Shusen Wang, Yunfang Yu, Zhongyu Yuan, Ying Wang, Herui Yao, Yuanyu Wen, Chengcai Yao
| Nature Verified
Abstract Maintenance therapy is key in prolonging remission and improving quality of life for hormone receptor-positive (HR + ), HER-2 negative (HER2-) metastatic breast cancer (MBC), but optimal strategies remain debated.
Open in Who Shared Issue with article?

Epithelial‐Mesenchymal Transition States and Metabolic Reprogramming Related Signatures Predict Prognosis and Therapeutic Responses in HER2‐Positive Breast Cancer

|
By Yuhui Zheng, Yinduo Zeng, Guoqiang Zhu, Mengping Xi
| Wiley Online Library Verified
1 Introduction According to the latest global cancer burden data released by the International Agency for Research on Cancer (IARC) of the World Health Organization, the number of new breast cancer cases worldwide reached 2.26 million in 2020, surpassing lung cancer (2.21 million cases) to become the world's largest cancer for the first time [1]. Breast cancer is the most common type of cancer in women, accounting for about 30% of female tumors, and the ratio of mortality to morbidity is 15% [2].
Open in Who Shared Issue with article?

Preclinical study and phase 2 trial of neoadjuvant pyrotinib combined with chemotherapy in luminal/HER2-low breast cancer: PILHLE-001 study

|
By Chang Gong, Yuan Xia, Yingying Zhu, Yaping Yang, Qun Lin, Qiang Liu, Wenqian Yang, Jiajie Zhong, Zhuxi Duan, Yunjie Zeng, Ziliang Cheng, Jun Shen, Yinduo Zeng, Erwei Song
| Cell Reports Medicine Verified
STAR★Methods REAGENT or RESOURCESOURCEIDENTIFIER Antibodies CD163 Abcam RRID: AB_2753196 CD68 Abcam RRID: AB_2801637 PD-1 CST RRID: AB_2864408 PD-L1 CST RRID: AB_2864409 CD3 Dako RRID: AB_2335677 CD4 Abcam RRID: AB_2750883 CD8 Abcam RRID: AB_2756374 CD56 Abcam RRID: AB_2632384 CD20 Dako RRID: AB_3075456 FOXP3 Abcam RRID: AB_445284 pan-CK Abcam RRID: AB_306047 S100 Abcam RRID: AB_882426 Biological samples Tumor samples This study N/A Critical commercial assays QIAamp DNA Mini Kit Qiagen Cat#:...
Open in Who Shared Issue with article?
See all 3 articles